Loading…
Abbott Laboratories is projected to rise to $96.07 by 2027, a +12% move from its current price of $85.68. ABT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $84.54 | $85.68 | $86.84 | 0.00% |
| May 30 | $84.07 | $85.69 | $87.33 | +0.01% |
| May 31 | $83.72 | $85.69 | $87.71 | +0.01% |
| Jun 1 | $83.42 | $85.69 | $88.02 | +0.01% |
| Jun 2 | $83.16 | $85.70 | $88.31 | +0.02% |
| Jun 3 | $82.93 | $85.70 | $88.56 | +0.02% |
| Jun 4 | $82.71 | $85.70 | $88.80 | +0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $82.71 | $85.70 | $88.80 | +0.03% |
| Week 2 | $81.52 | $85.72 | $90.14 | +0.05% |
| Week 3 | $80.63 | $85.74 | $91.19 | +0.08% |
| Week 4 | $79.88 | $85.77 | $92.08 | +0.10% |
| Week 5 | $79.24 | $85.79 | $92.88 | +0.13% |
| Week 6 | $78.66 | $85.81 | $93.61 | +0.15% |
| Week 7 | $78.13 | $85.83 | $94.29 | +0.18% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915.
Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Abbott Laboratories (ABT) is a healthcare company with a current price of $87.41 and a market cap of $152.25B. It ranks 99th by market capitalization in its sector.
A major floor 17.2% below — a decisive break under it would weaken the trend.
The nearest floor, 3.6% below — buyers have tended to step in here.
The nearest ceiling, 18.5% above — a clean break opens room to run.
A major ceiling 42.1% above — clearing it would confirm fresh momentum.
Key ABT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ABT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $87.18 | Sell | $86.68 | Sell |
| MA 10 | $86.58 | Sell | $86.83 | Sell |
| MA 20 | $86.83 | Sell | $88.12 | Sell |
| MA 50 | $95.15 | Sell | $94.36 | Sell |
| MA 100 | $104.87 | Sell | $102.53 | Sell |
| MA 200 | $117.04 | Sell | $111.19 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 37.27 | Neutral |
| Stoch RSI (14) | 68.22 | Neutral |
| CCI (20) | -41.74 | Neutral |
| Williams %R (14) | -50.16 | Info |
| MACD (12,26,9) | 0.70 | Buy |
| ROC (12) | 1.61 | Buy |
| Bollinger %B (20,2) | 0.37 | Neutral |
| Stochastic %K (14) | 49.84 | Neutral |
| TRIX (15) | -0.49 | Sell |
| Awesome (5,34) | -3.58 | Sell |
| Ultimate (7,14,28) | 52.10 | Neutral |
| Momentum (10) | 1.33 | Buy |
| Aroon Osc (25) | -36.00 | Sell |
| Hull MA (9) | 86.85 | Sell |
| ADX (14) | 32.18 | Sell |
| ATR (14) | 1.16 | Info |
The 30-day technical picture is neutral. The RSI(14) is 40, with the simple moving average for 50 days at $96.06 and the 200-day average at $117.51. There is a defined support at $82.56 and a resistance at $101.56, with a 30-day price range of $79.72 to $95.84.
The current price of $87.41 sits between these levels, indicating no clear near-term breakout. Traders may monitor for a move above $101.56 to signal a potential upside push.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $82.56 | $85.68 | $110.30 | 0% | Neutral | |
| $78.49 | $96.07 | $123.10 | +12% | Neutral | |
| $80.99 | $100.95 | $132.73 | +18% | Neutral | |
| $81.36 | $102.94 | $138.17 | +20% | Bullish | |
| $86.45 | $110.85 | $151.40 | +29% | Bullish | |
| $96.20 | $124.84 | $173.17 | +46% | Bullish | |
| $109.57 | $143.78 | $202.25 | +68% | Bullish | |
| $115.63 | $153.31 | $218.42 | +79% | Bullish | |
| $111.07 | $148.73 | $214.40 | +74% | Bullish | |
| $117.89 | $159.34 | $232.23 | +86% | Bullish | |
| $159.51 | $224.83 | $343.30 | +162% | Bullish | |
| $283.66 | $428.73 | $701.52 | +400% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $82.56 | $85.68 | $100.54 | +0.00% |
| June 2026 | $74.18 | $86.53 | $102.90 | +0.99% |
| July 2026 | $73.26 | $85.96 | $103.19 | -0.66% |
| August 2026 | $74.32 | $87.59 | $105.91 | +1.89% |
| September 2026 | $75.16 | $88.91 | $108.15 | +1.51% |
| October 2026 | $73.76 | $87.55 | $107.07 | -1.53% |
| November 2026 | $73.21 | $87.16 | $107.09 | -0.45% |
| December 2026 | $74.86 | $89.37 | $110.30 | +2.54% |
Click any year to see its month-by-month ABT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, ABT could reach as high as $110.30, with a base case around $85.68 and support toward $82.56 — roughly 0% from $85.68. Price action looks broadly range-bound.
Expect ABT to range from $78.49 to $123.10 through 2027. The $96.07 average target implies a +12% move from current prices. That is up +12% on the projected 2026 average. A consolidation phase looks the most probable path here.
The ABT price prediction for 2028 points to an average of $100.95 (low $80.99, high $132.73) — a potential gain of +18% on today's $85.68. Price action looks broadly range-bound.
In 2029, ABT is projected to trade between $81.36 and $138.17, averaging $102.94 — a potential gain of +20% from today's $85.68. That is up +2% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Abbott Laboratories's 2030 outlook centres on $110.85, within a $86.45 to $151.40 range. That is up +8% on the projected 2029 average. That marks a +29% change versus current levels. Momentum favours further upside here.
By 2031, ABT could reach as high as $173.17, with a base case around $124.84 and support toward $96.20 — roughly +46% from $85.68. Buyers look set to stay in control over this stretch.
Expect ABT to range from $109.57 to $202.25 through 2032. The $143.78 average target implies a +68% move from current prices. That is up +15% on the projected 2031 average. Momentum favours further upside here.
The ABT price prediction for 2033 points to an average of $153.31 (low $115.63, high $218.42) — a potential gain of +79% on today's $85.68. Buyers look set to stay in control over this stretch.
In 2034, ABT is projected to trade between $111.07 and $214.40, averaging $148.73 — a potential gain of +74% from today's $85.68. That is -3% versus the projected 2033 average. Momentum favours further upside here.
Abbott Laboratories's 2035 outlook centres on $159.34, within a $117.89 to $232.23 range. That is up +7% on the projected 2034 average. That marks a +86% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, ABT could reach as high as $343.30, with a base case around $224.83 and support toward $159.51 — roughly +162% from $85.68. Momentum favours further upside here.
Expect ABT to range from $283.66 to $701.52 through 2050. The $428.73 average target implies a +400% move from current prices. That is up +91% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ABT today (≈ 11.671335 ABT) could be worth
$5,003.87
+$4,003.87 (+400%) by 2050 · US Dollar
Based on the average projected ABT price of $428.73 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ABTwould be worth at today's price.
$1,000 invested in ABT on May 27, 2025 (≈ 7.52219 ABT) would be worth
$644.5
-$355.5 (-35.5%) today · 0.64× · US Dollar
Based on a ABT entry price of $132.94 vs. today's $85.68.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $88.38 | $969.45 | -3.1% |
| 1 month ago | $92.8 | $923.28 | -7.7% |
| 3 months ago | $116.26 | $736.97 | -26.3% |
| 6 months ago | $128.9 | $664.7 | -33.5% |
| 1 year ago | $132.94 | $644.5 | -35.5% |
| All time (5.0y) ago | $105.79 | $809.91 | -19.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ABT forecast.
Our base-case forecast reaches $170.00 around 2040.
Implied market cap at $170.00: $296.11B
The multi-year forecast shows a steadily higher average price path with bullish sentiment returning in later years. The 2026 forecast shows an average of $87.41, while 2027 is $98.01 and 2028 is $103.76. The outlook turns bullish in 2029 with an average of $105.90 and continues to rise, reaching an average of $113.73 in 2030 (ROI 30.1%) and $129.58 in 2031 (ROI 48.3%).
By 2032 the average is $148.78 (ROI 70.2%), and 2033 is $157.67 (ROI 80.4%), with 2034 at $154.13 (ROI 76.3%) and 2035 at $165.37 (ROI 89.2%). The longer horizon shows significant upside, with 2040 averaging $233.90 (ROI 167.6%) and 2050 averaging $448.50 (ROI 413.1%), supported by bullish sentiment through these later years. The max values align with this uptrend, e.g., 2032 max $209.33 and 2033 max $224.67, while the 2040 max reaches $357.19 and 2050 max $733.93.
These are estimates and not guarantees, and actual results will depend on market conditions and other factors.
Tap a question to reveal the answer.
The 2030 forecast shows an average of $113.73 with a min of $88.69, a max of $155.38 and an ROI of 30.1%, with bullish sentiment.
The forecast shows a shift to bullish sentiment from 2029 onward, with the average price rising from $105.90 in 2029 to $113.73 in 2030 and up to $448.50 by 2050, corresponding to an ROI of up to 413.1% in the long term. Note that near term 2026 is neutral.
Yes. The forecast max values include $209.33 by 2032 and $224.67 by 2033, indicating ABT could surpass $200 in the early 2030s.
Current price is $87.41 and market cap is $152.25B.
The 30-day range is $79.72 to $95.84.
Abbott Laboratories Community Discussion
0Share your Abbott Laboratories price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.